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Constitutional chromosome deletions and duplications frequently predispose to the development of a wide variety of cancers. We
have developed a microarray of 6000 bacterial artificial chromosomes for array-based comparative genomic hybridisation, which
provides an average resolution of 750kb across the human genome. Using these arrays, subtle gains and losses of chromosome
regions can be detected in constitutional cells, following a single overnight hybridisation. In this report, we demonstrate the efficiency
of this procedure in identifying constitutional deletions and duplications associated with predisposition to retinoblastoma, Wilms
tumour and Beckwith–Wiedemann syndrome.
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Predisposition to a variety of cancer predisposition syndromes
occurs as a result of the inheritance of gains and losses of
chromosomes and chromosome regions. Currently, Giemsa-
banding analysis of constitutional chromosomes is the most usual
way of identifying these chromosome abnormalities. Typically,
these cytogenetic approaches can readily identify whole chromo-
some changes as well as intrachromosomal deletions, with a
maximum resolution of approximately 10 megabase (Mbp). The
limitation of these analyses is that they cannot always reliably
detect small chromosome deletions or amplifications. If the
regions of the chromosome involved are known, for example,
based on the clinical features of the syndrome, it is possible
(Kempski and Cowell, 1993; Cowell et al, 1994) to analyse the
chromosomes using fluorescence in situ hybridisation (FISH).
Duplications of small chromosome regions are harder to identify
by FISH, especially if the duplication is small and tandem. The
limitation of this FISH approach is that it is usually performed on a
locus-by-locus basis, which requires some clinical indication of the
part of the genome that is involved. Identifying the specific
chromosome abnormality in these patients can be important for
the clinical management of the patient, since the larger the
deletions the more severe the associated clinical phenotypes.
Despite the limitations of karyotype analysis, it has been the
cornerstone for providing the diagnosis of human chromosome-
related syndromes. A method that unequivocally identifies the
presence of the chromosome changes in a nonbias analysis and
also defines the exact region involved directly from DNA samples
in a relatively short time, would address most of the shortcomings
of cytogenetics-based approaches. Over the past several years, we
have been developing a hybridisation approach that allows an
analysis of chromosome deletions and amplifications, without
the need to study metaphase chromosomes. This approach is
referred to as array comparative genome hybridisation (CGHa),
and consists of a series of mapped BACs arrayed on a glass slide to
which DNA from test and control samples are competitively
hybridised (Hodgson et al, 2001; Snidjers et al, 2001; Cowell and
Nowak, 2003).
In previous reports, CGHa has been used in highly focused
studies using limited sets of BACs, but only from well-defined
regions of the genome. Thus, Veltman et al (2002) used CGHa
arrays which comprised o100 BACs from the subtelomeric
regions of the human chromosomes to identify subterminal
deletions. Similarly, Veltman et al (2003b) used approximately
100 BACs from chromosome 18 to specifically investigate the
deletions associated with congenital aural atresia, and approxi-
mately 100 BACs from chromosome 22 were used to identify
deletions of the NF2 gene in NF2 patients (Bruder et al, 2001). In
these cases, it was necessary to know where in the genome to look
and, if there has been any other genetic change in the genome,
these would be missed. Larger arrays have been used in the
analysis of a number of different cancers, but again the level of
resolution has been in the range of 1–1.5Mbp or less. Thus,
Wessendorf et al (2003) used an array of approximately 500 BACs
to study B-cell non-Hodgkin lymphoma, but these BACs only
sampled regions of the genome which had previously been shown
to be involved in this malignancy. Arrays containing approxi-
mately 2000 BACs were used to study renal cell cancer (Wilhelm
et al, 2002), bladder cancer (Veltman et al, 2003a) and a number of
cell lines (Fiegler et al, 2003), and could identify large genetic
changes. The resolution of the BAC arrays, however, is an
important consideration, since more dense arrays will detect
smaller deletions and amplifications, which, in turn, provide the
best opportunity to define the driver gene for the abnormality.
In this report, we describe an array of 6000 BACs, which provide
an average inter-BAC interval across the genome of 500kb. In a
single hybridisation, using as little as 50–100ng, numerical
chromosome abnormalities can be identified over the whole
genome at a far greater resolution than previous reports (Cowell
et al, 2003, 2004a, 2004b; Cowell and Nowak, 2004). We have used
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sthese CGH arrays to investigate their ability to define constitu-
tional chromosome abnormalities associated with a number of
different syndromes carrying deletions and duplications of varying
size. In all cases, the specific abnormalities could be detected,
which supports the idea that CGHa for this application could
replace conventional karyotype analysis for most of the cancer
predisposition syndromes that result from structural chromosome
abnormalities.
MATERIALS AND METHODS
DNA samples were prepared from lymphoblastoid cell lines
previously derived from peripheral blood leucocytes. These cell
lines were cultured in RPMI medium supplemented with 10%
foetal calf serum and 10mM glutamine.
BAC array generation
A genome-wide resource of B6000 FISH mapped, gene/marker
content verified, and sequenced BAC clones (Cheung et al, 2001)
from the RPCI-11 human BAC library are represented as
immobilised DNA targets on glass slides for array-based CGH
analysis). Each clone is spotted in duplicate at 280mm intervals
(see http://genomics.roswellpark.org for a complete list of clones).
The average inter-BAC interval on the array is approximately
500kb, although the regions flanking the centromeres of all of the
chromosomes are relatively under-represented, because of the high
density of repetitive elements.
DNA preparation
Genomic DNA was prepared from all samples using the FlexiGene
DNA Isolation kit (Qiagen, Inc.). according to the manufacturer’s
instructions. Two control DNA pools are used for BAC CGH array
analysis. The male control and female control pools each contain
DNA from 15 cytogenetically normal individuals. For procedural
quality control, all analyses are performed as sex-mismatch
hybridisations. This allows determination of chromosome X and
Y copy number as an internal reference standard (see Figure 1).
Labelling of DNA
A measure of 1mg of control and test genomic DNA was random
primer labelled using a BioPrime DNA labelling kit (Invitrogen,
Inc.) for 3h at 371C, with the appropriate Cyanine dye (Cy3 or
Cy5). After ethanol precipitation, the probes are resuspended in
H2O and combined. Unincorporated Cy dye is removed by passage
over a Qiagen spin column. The labelled probes are dried and
stored at  201C until hybridisation.
Hybridisation
Briefly, the arrays are preblocked with 110ml Ambion SlideHyb
Buffer #3, 1mlo f2 0mgml
 1 Human Cot-1 DNA solution at 501Ci n
a GeneTAC hybridisation station (Genomic Solutions, Inc.) for
30min. Prior to hybridisation, the probe is resuspended in 110ml
Ambion SlideHyb Buffer #3 containing 5mlo f2 0mgml
 1 Cot-1 and
5ml of 100mgml
 1 yeast tRNA, heated to 951C for 5min and placed
on ice. The prehybridisation buffer is removed, the entire probe
added to the hybridisation chamber, and hybridisation proceeds
for 16h at 651C in the GeneTAC. After hybridisation, the slide is
washed in decreasing concentrations of SSC and SDS, followed by
one 0.1  SSC wash, one 95% EtOH rinse and centrifugal drying
for 3min.
Image analysis
The hybridised slides are scanned using an Affymetrix 428 Scanner
to generate high-resolution (10mm) images for both Cy3 and Cy5
channels. Image analysis is performed on the raw image files using
ImaGene (V4.1BioDiscovery). Each spot is defined by a circular
region, the size of which is programmatically adjusted to match the
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Figure 1 CGHa profile of constitutional DNA from patient GOS 115. The individual BACs for all chromosomes show a test/control ratio about a mean
of 0 (no change, log scale), with the exception of the 13q14 region where the ratio is  0.5, indicating the presence of a heterozygous deletion (see text).
The sex chromosome mismatch for this male patient was an XX control, which demonstrates a ratio or  0.5, which is expected in this experiment for a
hemizygous deletion.
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ssize of the spot. A buffer region of 2–3 pixels around the spot is
ignored and a region 2–3 pixels wide outside the buffer region is
considered the local background for that spot. Each spot and its
background region are segmented using a proprietary optimised
segmentation algorithm, which excludes pixels that are not
representative of the rest of the pixels in that region. The
background corrected signal for each BAC is the mean signal (of
all the pixels in the region) minus the mean local background. The
output of the image analysis is in the form of two tab-delimited
files, one for each channel, containing all of the fluorescence data.
Data analysis
The output of the image analysis is processed by a program written
in Perl and R, developed at RPCI. For each spot, the ratio is
calculated from the background subtracted mean signal of the two
channels. The ratios are then normalised on the log scale with a
nonlinear normalisation algorithm. Basically, for all spots that are
flagged as having met the qualitative spot criterion, the log2
background subtracted mean signal is plotted and a lowess
function is applied. The normalised ratios are the computed ratios
minus the expected values on the curve.
The results of the triplicate replicas are combined by taking the
mean of the log2 ratios and the standard error is calculated. Any
BAC that has less than two replicates flagged as having met the
qualitative spot criterion is excluded. Mapping information is
added to the resulting ratios and standard errors. The mapping
data for each BAC are found by querying the human genome
sequence at http://genome.ucsc.edu. The Nov 14 2002 build is
currently being used to precisely position the BAC clones on the
draft sequence. The output, a tab delimited file, is imported to
Excel for graphing.
Interpretation
The final ratio represents the relative amounts of DNA from the
experimental sample and the reference control sample. Equal
amounts of control and test DNA are labelled and the ratios are
normalised to 1 (0 on the log scale), effectively normalising the
array to the average modal number of the test sample. Knowledge
of the sex of the test sample is used to perform a sex mismatch
between the test sample and the control, providing an internal
control for copy number. Typically, a degree of suppression is
observed in these ratios. The X chromosome, therefore, can be
used to estimate the amount of suppression when the test sample
has a normal number of sex chromosomes, that is, XX or XY.
RESULTS AND DISCUSSION
Using conventional cytogenetics retinoblastoma (Rb), patients
with mental retardation and dismorphic features have been
typically shown to carry deletions on the long arm of chromosome
13 involving the 13q14.3 region (Cowell et al, 1989a). These
deletions eliminate one copy of the retinoblastoma predisposition
gene (RB1). Small deletions, however, do not have the same range
of diagnostic clinical features, and screening all Rb patients
cytogenetically is cost prohibitive, since less than 10% will carry
deletions (Cowell et al, 1989a). The esterase-D (ESD) gene was
localised adjacent to RB1 (van Heyningen et al, 1975), such that
deletions involving this region could be identified by measuring
ESD activity in red blood cells from the patient. To identify these
deletions, we developed a screening procedure which involved
measuring the ESD activity in retinoblastoma patients (Cowell et al,
1986a). Since the ESD gene lies approximately 650kb centromeric
to RB1 (Young et al, 1988), this was the only chromosome-
independent approach for the detection of deletions at that time.
Esterase-D quantitation for the discovery of deletions was
occasionally confounded by the possibility that the proximal
breakpoint of the deletion separated the ESD and RB1 genes
(Cowell et al, 1987; Mitchell and Cowell, 1988). Although ESD
quantitation proved to be a very quick and effective screening tool
(Cowell et al, 1986a), the low endogenous activity of the rarer ‘2’-
allele meant that 2–2 homozygotes would often produce enzyme
levels in these patients that were close to 50% of the normal
controls (Cowell et al, 1986b). This was particularly problematic in
groups such as the Japanese population (Horai and Matsunaga,
1984), where the incidence of the 2-allele is significantly greater
(40%) than in Caucasian (10%) populations (Cowell et al, 1986a).
To assess the ability of the CGH BAC arrays to identify 13q14
deletions in Rb patients, we used DNA to perform the hybridisa-
tion derived from a series of lymphoblastoid cell lines (Cowell et al,
1989a) established from representative Rb patients with deletions
of varying length. An example of a complete genomic profile that is
produced from the 6000-clone BAC array is shown in Figure 1. All
of the chromosomes show clustering of the hybridisation ratios
about the mean of 0 (diploid on the log2 scale). The heterozygous
deletion in two patients (GOS 115 and GOS 191) was readily
identified as the only abnormality in the sample (Figure 2). The
1.5
1
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1.5
1
0.5
1.5
1
0.5
GOS 115
GOS 191
GOS 203
Figure 2 CGHa profile for patients with retinoblastoma. The deletions
(arrows) in 13q14 for GOS 115 and 13q14–22 in GOS 191 can be clearly
seen with a ratio of approximately –0.5. Patient GOS 203 shows a normal
profile for chromosome 13 with all BACs, clustering around a mean of 1
(linear scale).
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detectable (Cowell et al, 1989a) and this deletion was shown by
CGHa to extend between BACs RP11-11k16 (32.04Mbp) and RP11-
37i864 (64.09Mbp), which, based on the human genome sequence,
represents a distance of 32.05Mbp. The deletion associated with
patient GOS 115, however (Figure 2), was more subtle (Cowell et al,
1989a), and was seen as a subband deletion surrounding the RB1
locus. Our CGHa analysis demonstrates that, in fact, this deletion
spans the region of 13q14 between BACs RP11-20k19 (44.86Mbp)
and RP11-37i8 (64.09Mbp), which constitutes maximally 20Mbp.
This analysis, therefore, also provides an approximate relationship
between the DNA sequence and the appearance of deletions in
metaphase chromosomes at the 850-band resolution. The RB1 gene
is located at position 47.81–47.99Mbp along the long arm of
chromosome 13.
The CGHa data demonstrate some important empirical details
for interpretation of the profiles. The prediction from the XX/XY
mismatch is that, on the log scale, there should be a ratio of  1 for
DNA from males and þ1 for females. In fact, we consistently see
that this ratio is closer to 70.5. Although we do not know the full
cause of this suppression of the hybridisation ratio, we presume
that much of it is due to nonspecific hybridisation in the system,
most likely due to repetitive sequences which cannot be competed
out using Cot1 DNA (Cowell and Nowak, 2003). Despite this
reduction in hybridisation ratio, however, it is clear that deletions
and duplications (see below) show a change in ratio that is
consistent with that seen for the X chromosome in the same
experiment, which makes definition of the chromosome change
relatively easy.
During our analysis of retinoblastoma patients using ESD
screening, we identified a potential chromosome deletion in
patient GOS 203, where the enzyme levels were 50% of that seen
in normal controls (Cowell et al, 1986b). This patient was shown,
using starch gel electrophoresis, to be homozygous for the ‘2’
allele, which we had already shown had an inherently lower activity
than the 1-allele. Heterozygotes show reduced levels (Cowell et al,
1986b), but not large enough to suggest a 50% reduction in
activity. Patient 203 showed mild dismorphic features and reduced
cognitive ability. Chromosome analysis, however, appeared normal
but did not, together with the ESD levels and clinical phenotype,
rule out the presence of a submicroscopic deletion unequivocally.
Clearly, although a rare case, genetic counseling in this family was
inadequate, since we could not ignore the potential that she carried
a deletion based on the enzyme assays. These deliberations were
tempered by the lack of convincing cytogenetic data and the mild
clinical phenotype. The CGHa profile for chromosome 13 from this
patient is shown in Figure 2, and clearly shows diploid levels along
the length of the chromosome and in particular for BAC RP11-
174i10, which contains the RB1 gene. This result formally
demonstrates that this patient does not carry a 13q14 deletion.
Although it has been some time since genetic counselling was
given to this patient, the ESD result clearly influenced this family
in their choice not to have children at the time.
We next extended our CGHa analysis to patients who had been
reported as having 13q- syndrome which involves various partial
deletions in the q22-qter region (Luo et al, 2000; Gutierrez et al,
2001; Hewson and Carter, 2002). These patients have a well-defined
set of clinical phenotypes, including mental retardation, where the
deletion was generally assumed to involve the terminal region of
13q, although somatic cell hybrid studies (Hawthorn and Cowell,
1995) suggested that these were, in fact, subterminal deletions. In
this CGHa study, we analysed two patients, GOS 71 and GOS 107,
reportedly with 13q- syndrome (Figure 3). The syndrome in
patient GOS 71 included; hypertonia, small stature, low set
posteriorly rotated ears, bilateral simian creases, metatarsus varus,
cryptorchidism, high arched palate and wide alveolar margins. In
contrast, the features of patient GOS 107 included, developmental
delay, short stature, hearing impairment, tracheo-oesophageal
fistula, renal impairment and asthma. Although the prior
cytogenetic analysis had suggested the same diagnosis in these
cases, the clinical phenotypes were different and CGHa analysis
provided the basis for this. GOS 107 showed the typical deletion
involving the 13q31–33 region, but not including the telomere,
confirming that, in fact, this is an interstitial deletion which was
located between BACs RP11-86c3 (89.2Mbp) and RP11-7b23
(101.15Mbp), which spans a 12Mbp region. By contrast, GOS 71
showed a much more proximal deletion involving the 13q12–13
region, between BACs RP11-179a7 (33.2Mbp) and RP11-269c23
(43.87Mbp), a distance of 10.67Mbp. Clearly, although there is
some overlap in the clinical phenotype between these two patients,
the deletions are very different, which accounts for the discrepancy
in their clinical phenotype. Importantly, the original cytogenetic
diagnosis for GOS 71 was misinterpreted and this deletion does not
include RB1, which is located at 47.9Mbp.
The study of constitutional deletions on chromosome 13 clearly
has the advantage of speed, and accuracy of the diagnosis. To
extend our studies, we investigated DNA from other patients with
syndrome-related chromosome abnormalities. Aniridia is a rare
hereditary disease resulting in the absence of irises. In the familial
form, the phenotype segregates as an autosomal dominant
disorder due to mutations in the PAX6 gene (Davis and Cowell,
1993). Sporadic cases of aniridia show a 50% increased risk to the
development of Wilms tumour (WT), a pediatric cancer of the
kidney (Riccardi et al, 1978). In these patients, the cancer
predisposition results from the presence of a constitutional
deletion involving the 11p13 region containing both the WT1
and PAX6 genes. Patients with PAX6 gene mutations clearly
represent the hereditary form of the disease, and are not at
increased risk to the development of WT. From a genetic
counselling standpoint, a sporadic case of aniridia could either
carry a deletion predisposing to WT, or carry a de novo mutation
in the PAX6 gene. Therefore, being able to exclude the tumour risk
in these patients would involve either a mutation study of the PAX
6 gene, which is a complex and time-consuming procedure, or a
cytogenetic analysis of the 11p13 region. To assess the utility of the
CGHa approach in this situation, we used DNA from patient GOS
157, which we had previously demonstrated to carry a small
deletion involving the 11p13 region (Cowell et al, 1989b). The
1.5
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GOS 107
Figure 3 CGHa profiles for patients reportedly with 13q- syndrome. In
GOS 71, the deletion (arrows) is seen in the 13q12–14 region, whereas, in
patient GOS 107, the deletion (arrows) lies more distal in the 13q31–33
region.
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deletion is clearly seen in the short arm of chromosome 11,
spanning a distance between 26.62 and 44.6Mbp (18Mbp), which
includes the PAX6 and WT1 genes.
From the experiments described above, it is clear that CGHa can
be used to quickly and efficiently identify heterozygous constitu-
tional deletions, and could be easily extended to other syndromes
such as the 15q deletion associated with Angelman/Prader Willi
syndrome (Vogels and Fryns, 2002) or the 22q deletions associated
with Di George syndrome (Baldini, 2002). Other genetic syn-
dromes, however, are associated with extra copies of small
chromosome regions. An example of this (Mannens et al, 1994)
is the chromosome imbalance that is associated with the pediatric
cancer predisposition syndrome, Beckwith–Wiedemann syn-
drome (BWS). In these cases, it has been demonstrated that
duplication of a region in 11p15, which results in three copies of
the 11p15.5 region, is responsible for the phenotype in some cases.
BWS may sometimes be confused with the phenotypically similar
Perlman’s syndrome, which has a much higher frequency of cancer
than BWS (Grundy et al, 1992), and for which no chromosome
abnormality has yet been identified. To determine whether these
types of chromosome aberration can also be detected using CGHa,
we analysed the DNA from a patient who had been shown by
extensive molecular and cytogenetic analysis to carry a non-
reciprocal chromosome translocation t(5;11)(p15;p15), which
resulted in the triplication of the 11p15 region (Grundy et al,
1998). The CGHa profile from this patient, GOS 637, is shown in
Figure 4, and demonstrates that the translocation event is more
probably the result of an insertion of the 11p 15.5 region spanning
BACs RP11-120e20 (3.67Mbp) and RP11-6k5 (20.37Mbp), cover-
ing 16.77Mbp, in the distal region of 5p15. On the log scale, all of
the BACs in this region show an intensity ratio of þ0.5,
confirming the presence of an extra copy of this region. The most
distal BACs (0–3.67Mbp), however, show a ratio closer to 1. The
most telomeric BAC on the array, RP11-123f4, is clearly only
present in a diploid complement and, although the adjacent series
of BACs show a ratio of 1.2, this is still within the range of ‘noise’
shown for the other BACs along the chromosome, suggesting this
region is also present in only two copies. Thus, although the
diagnosis of BWS is not at issue, this analysis provides valuable
information about the extent, and hence the gene content, of the
region involved.
Our CGHa analysis of constitutional chromosome abnormal-
ities, therefore, provides a demonstration that heterozygous,
predisposing chromosome deletions and duplications can easily
be detected and accurately defined. The high resolution of this
array means that small chromosome deletions, which cannot be
detected using conventional chromosome analysis, will also be
identified. The other advantage of CGHa is that only small
amounts of DNA are required for the hybridisation, without the
need for the preparation of metaphase chromosome spreads,
which means that the analysis can be performed using DNA from
nondividing tissue such as buccal swabs or skin biopsies. As a
consequence, the diagnosis can be made in a relatively short time,
since there is no need for extensive culture periods for sample
preparation. One area where this advantage would be particularly
useful is in the analysis of amniotic fluid cells or chronic villous
samples for prenatal diagnosis of hereditary chromosome
abnormality syndromes. The rapid turn around time associated
with CGHa also presents clear advantages for the clinical
management of these patients, and has important implications
for genetic counselling.
The analysis of specific chromosome deletions has frequently
led to the discovery of the gene(s) involved in the associated
phenotype. The ability of CGHa to clearly define the gene content
within the deleted or amplified region and to compare these
observations between patients provides a rapid way of selecting
candidate genes for more detailed study.
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